CSPG4 and melanoma: To evaluate the feasibility of combining CSPG4-CAR-T cells with BRAF and MEK inhibitors (BRAFi/MEKi), which are part of the standard therapy of melanoma, our group assessed several canonical effector functions of CSPG4-CAR-T cells in the presence of clinically-approved BRAFi/MEKi combinations [56].